Anticoagulation for Atrial Fibrillation in Acute Coronary Syndrome Survivors Reduces Major Cardiovascular Events and Mortality.
Łukasz PykaBartosz HudzikStanisław BartuśPaweł BuszmanMarek GierlotkaWojciech WojakowskiJarosław HiczkiewiczAndrzej KleinrokMichał SkrzypekWiktor KuliczkowskiMariusz GąsiorPublished in: Journal of cardiovascular pharmacology and therapeutics (2024)
This all-comer national registry analysis shows that the use of guideline-recommended therapy and anticoagulation in ACS survivors with AF is associated with a lower rate of all-cause mortality, recurrent myocardial infarction, and ischemic stroke.
Keyphrases
- atrial fibrillation
- cardiovascular events
- acute coronary syndrome
- coronary artery disease
- oral anticoagulants
- heart failure
- catheter ablation
- left atrial
- percutaneous coronary intervention
- cardiovascular disease
- left atrial appendage
- young adults
- direct oral anticoagulants
- antiplatelet therapy
- quality improvement
- left ventricular
- stem cells
- mesenchymal stem cells
- cell therapy